ID   CLF_PEDS0005_T2A
AC   CVCL_C9B4
SY   CLF_PEDS0005_T2a
DR   BioGRID_ORCS_Cell_line; 1223
DR   dbGAP; phs001800.v1.p1
DR   GEO; GSM3039705
DR   Wikidata; Q123030937
RX   PubMed=30860482;
CC   Population: African American.
CC   Sequence variation: Gene fusion; HGNC; HGNC:28667; C1orf116 + HGNC; HGNC:11103; SMARCB1; Name(s)=SMARCB1-C1orf116; Note=SMARCB1 intron 1 fused to C1orf116 C-terminal (from autologous cell line CLF_PEDS0005_T1).
CC   Sequence variation: Gene deletion; HGNC; HGNC:11103; SMARCB1; Zygosity=Heterozygous (from autologous cell line CLF_PEDS0005_T1).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C7572; Kidney medullary carcinoma
DI   ORDO; Orphanet_319319; Renal medullary carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C9B2 ! CLF_PEDS0005_N
OI   CVCL_C9B3 ! CLF_PEDS0005_T1
OI   CVCL_C9B5 ! CLF_PEDS0005_T2B
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 19-12-24; Version: 3
//
RX   PubMed=30860482; DOI=10.7554/eLife.44161; PMCID=PMC6436895;
RA   Hong A.L., Tseng Y.-Y., Wala J.A., Kim W.-J., Kynnap B.D., Doshi M.B.,
RA   Kugener G., Sandoval G.J., Howard T.P., Li J., Yang X.-P., Tillgren M.,
RA   Ghandi M., Sayeed A., Deasy R., Ward A., McSteen B., Labella K.M.,
RA   Keskula P., Tracy A., Connor C., Clinton C.M., Church A.J.,
RA   Crompton B.D., Janeway K.A., Van Hare B., Sandak D., Gjoerup O.V.,
RA   Bandopadhayay P., Clemons P.A., Schreiber S.L., Root D.E.,
RA   Gokhale P.C., Chi S.N., Mullen E.A., Roberts C.W.M., Kadoch C.,
RA   Beroukhim R., Ligon K.L., Boehm J.S., Hahn W.C.;
RT   "Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive
RT   to proteasome inhibition.";
RL   eLife 8:e44161.1-e44161.32(2019).
//